James B. Kaper is a Professor and Chair of the Department of Microbiology & Immunology at the University of Maryland School of Medicine. He serves as Vice Dean for Academic Affairs and previously held leadership roles as Senior Associate Dean (2014–2019) and Chair (2007–present). His research focuses on the molecular pathogenesis of diarrheagenic Escherichia coli and Vibrio cholerae , including vaccine development and bacterial-host interactions. Education: BS (1973) and PhD (1979) in Microbiology from University of Maryland; Postdoc in Molecular Pathogenesis at University of Washington (1979–1981) Dr. Kaper’s work has led to the creation of live attenuated cholera vaccines, including CVD 103-HgR, the first licensed recombinant bacterial vaccine. His lab investigates bacterial genetics, intestinal colonization, and immune system activation, particularly TLR5 response to V. cholerae flagellin. He has authored 303 peer-reviewed articles and 68 book chapters. His research has been funded continuously by NIAID since 1982. Key publications include foundational work on V. cholerae vaccines (1984), genomic structure (1998), and quorum sensing in EHEC/EPEC (1999). His lab’s recent studies focus on phosphotyrosine proteomics (2013) and pathogenicity island regulation (2007). Scientific awards: Fellow, American Academy of Microbiology (1994); NIH Merit Award (2004); ASM DC White Award (2019) Editorial roles: Editor-in-Chief, EcoSal (2006–present); Associate Editor, International Journal of Medical Microbiology (2000–present) As an academic leader, Dr. Kaper has mentored over 60 graduate students and postdoctoral fellows. He holds multiple patents for cholera vaccines and E. coli diagnostics, including U.S. Patents 4,935,364; 5,399,494; and 6,204,004. His lab at UMSOM combines basic science with translational applications for enteric disease prevention.
Kelly Arnold is an Associate Professor in the Department of Biomedical Engineering at the University of Michigan. Her research integrates systems engineering principles with immunology to investigate variability in immune responses across infection, vaccination, and injury, with a focus on computational modeling and clinical translation. Research Focus Systems-level immune response modeling Vaccination and antibody functionality Vaginal microbiome-host interactions Chronic lung disease progression Computational serology and proteomics Recent Work Her 2025 studies examine SARS-CoV-2 vaccination responses in cancer patients and computational frameworks for vaginal probiotics. Earlier works (2024-2007) span COPD progression, lupus fibrosis, HIV susceptibility, and tissue engineering for fertility preservation. Methodologies include proteomic profiling, network modeling, and microfluidic systems.
Pinar Keskinocak serves as the H. Milton and Carolyn J. Stewart School Chair and Professor in the H. Milton Stewart School of Industrial and Systems Engineering at the Georgia Institute of Technology. She co-founded and directs the Center for Health and Humanitarian Systems, demonstrating leadership in both academic administration and research innovation. Her career includes prior roles as College of Engineering ADVANCE Professor and interim associate dean for faculty development, alongside industry experience at IBM T.J. Watson Research Center. Her educational foundation includes a Ph.D. in Operations Research from Carnegie Mellon University and M.S. and B.S. degrees in Industrial Engineering from Bilkent University. This rigorous training underpins her interdisciplinary approach to complex societal challenges. Dr. Keskinocak's research pioneers operations research applications for societal impact , with dual emphases on health systems and humanitarian logistics . She develops advanced models for infectious disease dynamics (including COVID-19, malaria, and Guinea worm), vaccination strategies, disaster response, and supply chain optimization. Her work uniquely bridges engineering analytics with real-world implementation through partnerships with the CDC, American Red Cross, Carter Center, and Children's Healthcare of Atlanta. Analysis of her 2023-2025 publications reveals intensifying focus on eradication program modeling for polio and Guinea worm, with increasing integration of machine learning for predictive accuracy in vaccine distribution. A pronounced trend addresses health equity through targeted interventions for under-immunized populations in Sub-Saharan Africa, emphasizing resource allocation under constraints and cross-border coordination challenges. Her scientific recognition includes: INFORMS Fellow (2015) NSF CAREER Award (2001) Outstanding Professional Education Award, Georgia Tech (2018) Denning Award for Global Engagement, Georgia Tech (2016) Women in Engineering Excellence Teaching Award (2005) Moving Spirit Award, INFORMS (2005) Dr. Keskinocak has secured extensive project funding through collaborations with federal agencies and NGOs, directing research on pandemic response systems, vaccine logistics, and disaster debris management. While specific advisees aren't publicly cataloged, her leadership in the Center for Health and Humanitarian Systems mentors numerous graduate researchers through interdisciplinary projects. She significantly influences national policy via National Academies committees addressing supply chain resilience and vaccine distribution infrastructure. The Center for Health and Humanitarian Systems operates as a dynamic hub where engineering rigor meets humanitarian action, coordinating multi-institutional teams to develop deployable solutions for global health crises and disaster response systems.
Lars Engstrand is a Professor in infection control at Karolinska Institutet, heading the Translational Microbiome Research and Pandemic Preparedness group within the Department of Microbiology, Tumor and Cell Biology. His research spans multiple disciplines with a focus on translational microbiome research and pandemic preparedness. Engstrand's research interests center on understanding the human microbiome's role in health and disease, particularly in women's reproductive health and gastroenterology. His group has established multiple large-scale clinical studies including SweMaMi (Swedish Maternal Microbiome project), BASIC (associations between microbiota and preterm birth), VaMiGyn (Vaginal Microbiota in Gynaecological health), and several others investigating the vaginal microbiome's relationship to pregnancy outcomes, HPV infection, and cervical cancer. His team also conducts significant research on gut microbiome in inflammatory bowel disease and colorectal conditions through projects like PopCol and KOLBIBAKT. Analysis of Engstrand's most recent publications reveals a strong focus on the relationship between microbiome composition and women's health outcomes. His research consistently examines how vaginal, gut, and oral microbiomes influence pregnancy complications, preterm birth, HPV infection, and mental health during pregnancy. The work often employs large cohort studies with comprehensive sampling strategies across multiple body sites and time points, providing robust data for understanding microbiome dynamics in health and disease. Engstrand leads the Microbiome Exploration and Development for Intervention (MEDI) initiative and the National Pandemic Center (NPC) at Karolinska Institutet. The NPC conducted large-scale sequencing during the COVID-19 pandemic and has amassed over 1.5 million samples. His research group includes multiple specialized teams focusing on culturomics, bioinformatics, labcore operations, women's health research, and pandemic preparedness.
Mohammad Peydayesh is a Lecturer and Senior Researcher at the Department of Health Sciences and Technology , ETH Zürich. He works in the Food and Soft Material Laboratory , focusing on sustainable materials derived from food waste and agri-food byproducts. PhD in Chemical Engineering (2018, Iran University of Science and Technology) Postdoctoral Fellow at ETH Zürich under Prof. Dr. Mezzenga Senior Assistant at ETH Zürich since 2021 His research spans soft matter , self-assembly phenomena , and amyloid fibril applications in: Environmental engineering (water purification, heavy metal removal) CO2 conversion and storage Smart packaging and bioplastics development Biorefinery concepts and circular economy Nanomaterials for waste valorization Recent publications highlight trends in amyloid-based hybrid materials for: Metal recovery from e-waste and contaminated water CO2 capture and conversion Bioplastic production from agricultural waste Antiviral and detoxification applications Water desalination and purification Photonic and catalytic materials He contributes to the Laboratory of Food & Soft Materials , advancing sustainable solutions through interdisciplinary material science.
Santiago F. González is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, and an extraordinary professor at the University of Italian Switzerland (USI). He earned dual PhDs in microbiology (University of Santiago de Compostela, Spain) and immunology (University of Copenhagen, Denmark), followed by postdoctoral work (2007–2011) at Harvard Medical School's Immune Disease Institute under Michael Carroll. PhD in Microbiology, University of Santiago de Compostela PhD in Immunology, University of Copenhagen His research focuses on immune system dynamics during respiratory viral infections, vaccination, and cancer metastasis. Key areas include influenza recognition , lymph node inflammation , and immune cell behavior in vivo. He pioneered studies on C-type lectin receptors (e.g., SIGN-R1) in viral immunity and epigenetic modulators for inflammation. Recent publications highlight his work in epigenetic drug development , nanovaccines , and computational tools for immune cell tracking. His group uses two-photon intravital microscopy and spatial-temporal modeling to dissect immune responses. Scientific awards include three EU Marie Curie Fellowships (2004–2013), enabling his transition to independent research. His collaborations span Harvard, USI, and European institutions, with grants from the EU and Swiss research bodies. His lab at IRB, established via the 2013 Marie Curie Career Integration Grant , develops novel imaging approaches and therapeutic strategies for infectious and immune-mediated diseases.
Jeff Schorey is the George B. Craig Jr. Professor and a full Professor in the Department of Biological Sciences at the University of Notre Dame, where he has been a faculty member since 2004. He currently serves as Director of the Integrated Biomedical Sciences (IBMS) graduate program and previously held leadership roles including Chair of the Institutional Animal Care and Use Committee (IACUC) and Associate Director of the Eck Institute for Global Health. His research focuses on the pathobiology of mycobacterial diseases, particularly Mycobacterium tuberculosis and M. avium . His work investigates the molecular interactions between mycobacteria and host macrophages, with a special emphasis on the role of exosomes in immune modulation, diagnostics, and vaccine development. He also explores novel antibiotic development in collaboration with chemists at Notre Dame and global partners. His recent publications reveal a strong trend in extracellular vesicle biology, host-pathogen signaling, and translational applications in TB diagnostics and treatment. The articles span immunology, microbiology, and molecular biology, with recurring themes in exosome function, RNA sensing, and antimicrobial development. George B. Craig Jr. Collegiate Professor Dr. Schorey has advised graduate students and leads an active research lab focused on mycobacterial pathogenesis. His work is supported by collaborations across disciplines and institutions, particularly in drug development and clinical translation. He has contributed significantly to understanding how exosomes can serve as both biomarkers and therapeutic tools. His lab employs cellular immunology, animal models, and clinical sample analysis to study mycobacterial infections. He leads the IBMS program, shaping graduate education in biomedical sciences at Notre Dame.
University of North Carolina at Chapel HillUnited States
Juliane Nguyen, PhD, is a Professor in the Department of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill. She serves as Vice Chair and Director of Graduate Admissions in her department and holds an adjunct appointment as Professor of Biomedical Engineering. Dr. Nguyen is also a member of the UNC Lineberger Comprehensive Cancer Center, where she applies molecular engineering approaches to develop innovative therapeutic solutions. Dr. Nguyen's research focuses on molecular engineering to advance protein-based therapeutics, live biotherapeutics (including engineered probiotic yeast), and extracellular vesicles. Her lab develops cutting-edge technologies to treat diverse conditions including cancer, myocardial infarction, chemotherapy-induced cardiotoxicity, and inflammatory bowel diseases. Her interdisciplinary approach integrates molecular engineering, pharmaceutical sciences, and bioinformatics to create complex biologics with exceptional safety and efficacy profiles. Key research areas include developing therapeutics for cardiac repair, genetically encoded materials targeting tumor-associated macrophages, live biotherapeutics for inflammatory bowel diseases using engineered probiotic yeast, and auxetic patches for dynamic organ repair. Analysis of Dr. Nguyen's recent publications reveals a strong focus on translational research with significant contributions to cardiac repair technologies, cancer immunotherapy, inflammatory bowel disease treatments, and advanced biomaterials. Her work consistently bridges fundamental molecular engineering with clinical applications, particularly in the areas of targeted drug delivery, extracellular vesicle therapeutics, and engineered live biotherapeutics. The research demonstrates a clear trajectory toward developing clinically viable solutions for previously challenging medical conditions. Dr. Nguyen has received numerous prestigious awards and honors including the NSF CAREER Award (2018), Eshelman Innovation Award (2020), and recognition as a Fellow of the Controlled Release Society (2023). She was appointed as a Standing Member of the NIH Drug and Biologic Therapeutic Delivery Study Section (2023-2025) and serves as Executive Editor of Advanced Drug Delivery Reviews since 2021. Her Galenus Guest Professorship at ETH Zuerich (2024) and keynotes at major conferences highlight her international recognition in the field. As Director of Graduate Admissions and an active mentor, Dr. Nguyen has advised numerous PhD and Master's students who have co-authored significant publications with her. Her research is supported by competitive grants including the NSF CAREER Award and other NIH-funded projects. The Nguyen Lab maintains strong collaborations across disciplines, particularly with cardiology, oncology, and biomedical engineering researchers. She leads an interdisciplinary team focused on translating molecular engineering breakthroughs into clinically impactful therapies. The Nguyen Lab operates as a dynamic, interdisciplinary research environment combining expertise in molecular engineering, pharmaceutical sciences, and bioinformatics. The lab's mission is to revolutionize medicine by developing next-generation therapeutics that target diseases at the molecular level. Current projects focus on translating cutting-edge research into life-changing therapies for patients suffering from cancer, myocardial infarction, colitis, and other challenging conditions. The lab's innovative approach to biomolecular engineering positions it at the forefront of developing safe, effective, and personalized therapeutic solutions.
Professor Ali Gilles Tchenguise Miserez holds a joint appointment as Professor in the School of Materials Science and Engineering and the School of Biological Sciences at Nanyang Technological University (NTU) in Singapore. He is also the President's Chair in Materials Science and Engineering. His research group, the Biological and Biomimetic Materials Laboratory (BBML), is highly interdisciplinary, bringing together molecular biologists, chemists, bio-physicists, and materials scientists to study natural materials with unique properties not found in man-made materials. Prof. Miserez's research interests span multiple areas including bioelastomeric membranes & coiled-coil engineering, mechanisms of biofouling adhesion & anti-adhesive coatings, molecular biomimetics of non-mineralized hard tissues, biomineralized structures with graded properties, and liquid-liquid phase separation. His work focuses on understanding the molecular, physico-chemical, and structural principles of biological materials and translating these designs into novel biomimetic synthesis strategies. His laboratory emphasizes "green chemistry" approaches that mimic nature's energy-efficient synthesis methods under ambient conditions. Prof. Miserez's publication record demonstrates significant impact across multiple disciplines, with work appearing in top journals including Science, Nature Materials, Nature Biotechnology, Nature Chemical Biology, and Advanced Materials. His recent research has particularly focused on peptide coacervates for intracellular delivery of therapeutics, with applications in cancer treatment, mRNA delivery, and nucleic acid therapeutics. This work represents a convergence of materials science, biochemistry, and medicine with significant translational potential. Singapore National Research Foundation (NRF) Fellowship (2011) - $3 Million individual research grant for early career scientists Prof. Miserez has mentored numerous PhD students and postdoctoral researchers, many of whom have gone on to successful careers in academia and industry. His laboratory has developed strong international collaborations and has secured significant research funding. Current projects include developing peptide-based delivery systems for cancer therapeutics, understanding marine biofouling mechanisms, and creating biomimetic materials inspired by natural systems. The BBML laboratory is actively recruiting talented researchers interested in interdisciplinary work at the interface of biology and materials science.
Prof. Friederike Ebner holds the Chair of Infection Pathogenesis at the Technical University of Munich (TUM) since 2023, within the TUM School of Life Sciences. Her research focuses on the immunobiology of parasite infections, particularly studying gastrointestinal helminths like Ascaris suum and their interactions with host immune systems to design novel intervention strategies. She also develops biomedical models for studying infectious diseases. Educational Background: Friederike Ebner earned a biotechnology degree from TU Berlin and Dongseo University (South Korea). She completed her PhD in biology at Humboldt University Berlin (2014), followed by postdoctoral research in immunology at Freie Universität Berlin, where she became an assistant professor before moving to TUM. Research Interests: Her work spans helminth-host immune dynamics, vaccine development, microbiome interactions in parasitic infections, and translational models for human diseases. Key topics include Th2/Th1 immune balance, helminth-derived immunomodulators, and xenotransplantation safety. Notable Contributions: Her recent studies address diagnostic methods for ascariasis, microbiome roles in helminth survival, and immunotherapeutic applications of parasite products. Current efforts emphasize bridging fundamental immunology with clinical and veterinary applications. Professional Activities: Prof. Ebner teaches immunology and parasite biology at TUM while maintaining active collaborations in global health and infectious disease research. She advocates for interdisciplinary approaches to address knowledge gaps in parasitology and vaccinology.
Dr. Rajendra Kurapati is an Assistant Professor at the School of Chemistry , Indian Institute of Science Education and Research Thiruvananthapuram (IISER TVM) . His research focuses on biodegradable 2D materials for biomedical applications, addressing nanomaterial biopersistence issues through enzymatic degradation studies. He leads the Biomaterials Lab and collaborates with institutions across France, Ireland, Portugal, and the UK. Born in Andhra Pradesh, India B.Sc. & M.Sc. in Chemistry (Acharya Nagarjuna University, University of Hyderabad) Ph.D. in Materials Engineering (Indian Institute of Science, 2014) Postdoc: CNRS Strasbourg (2014-2017), CÚRAM Galway (2018-2020) His research explores 2D material-biopolymer hybrids for drug/gene delivery , nanotheranostics , and antimicrobial coatings . Key article trends include: Graphene/MoS2 biodegradation by human enzymes Antibacterial coatings for medical implants Microplastics' environmental impact Lipid nanoparticles for mRNA vaccines ZnO quantum dots for bioimaging Polymer multilayer drug delivery systems Major scientific awards : DBT Ramalingaswami Fellowship (INR 40 lakhs over 5 years) SERB Start-up Grant (32 lakhs over 2 years) SERB Special Grant (45 lakhs over 3 years) DBT Mission Innovation Grant (18 lakhs over 6 months) His academic contributions span 15+ high-impact publications in journals like Advanced Materials , Nanoscale , and Chemical Communications , covering topics from graphene biodegradation to antimicrobial coatings and bioimaging . 10+ alumni students have graduated from his lab, with placements at institutions including University of Strasbourg and Dublin City University.
Anna Salvati is an Associate Professor specializing in nanomedicine and drug delivery systems. Her research focuses on nanoparticle-cell interactions, biomolecular corona formation, and the physicochemical properties governing nanomaterial behavior in biological environments. Key research themes include cellular uptake mechanisms, toxicity of nanomaterials, and nanoparticle targeting strategies. Recent publications highlight her work on nanoparticle stability, membrane interactions, and environmental impacts of microplastics. Her studies integrate multiomics approaches, advanced imaging, and interlaboratory validation to address challenges in nanomedicine design and safety testing. Current projects explore the role of high-density lipoproteins in nanoparticle functionality and the modulation of drug release kinetics through material engineering.
Swiss Federal Institute of Technology in LausanneSwitzerland
Maartje Bastings is an Associate Professor at the École Polytechnique Fédérale de Lausanne (EPFL) , leading the Programmable Biomaterials Laboratory (PBL) within the School of Engineering (STI) . She holds additional affiliations with the Institute of Materials (IMX) , IBI-STI (Bioengineering), and supervises doctoral programs in Biotechnology and Biological Engineering ( EDBB-GE ) and Materials Science and Engineering ( EDMX-GE ). Her research focuses on DNA-based supramolecular materials engineered to achieve dynamic reciprocity —a two-way interaction between synthetic materials and biological systems. By leveraging DNA as a programmable scaffold, she investigates structural mechanics, valency control, and geometric constraints governing self-assembly and cell communication at bio-interfaces. Key applications include immune system modulation, diagnostics , and vaccine development . Analysis of her 15 most recent publications reveals a focus on multivalent interactions for T-cell activation, spatial patterning in immune signaling, and engineered coatings for DNA origami stability. Subfields span T cell receptor engineering , nanoscale protein dynamics , stimuli-responsive biomaterials , and bio-inspired therapeutic design . PhD Students: Chen Yuduo Hendrickx Pauline Bart M. Kononenko Artem Li Shujie Lou Yameng Meyer Pitt Narita Minako Rousseau Benjamin Bila Hale Caroprese Vincenzo Comberlato Alice Kurisinkal Eva Eugene Paloja Kaltrina Rodríguez Franco Hugo José Tekin Cem Wong Siu Ho Contact: maartje.bastings@epfl.ch
Dr. Tonghui Jin serves as a Researcher at ETH Zurich's Institute of Food, Nutrition and Health within the Department of Health Sciences and Technology. Based at the Laboratory of Food & Soft Materials (Schmelzbergstrasse 9, Zürich), her work bridges fundamental protein science with industrial applications in sustainability and healthcare. Her research centers on amyloid fibril engineering for multifunctional biomaterials, with three core thrusts: Environmental Solutions : Developing amyloid-based membranes for PFAS water remediation and amine-functionalized aerogels for CO2 capture Biomedical Innovation : Creating microneedle patches for diabetic wound healing and toxin-responsive nanovaccines against bacterial infections Advanced Materials : Engineering structural color systems from amyloid liquid crystals and superwetting functional coatings These efforts leverage protein nanofibrils' unique mechanical and catalytic properties to address global challenges in resource recovery and health. Analysis of her 2021-2025 publications reveals a strategic shift toward catalytic amyloid hybrids, with 60% of recent work focusing on CO2 conversion, lithium recovery, and enzymatic detoxification. The interdisciplinary nature spans materials chemistry, environmental engineering, and biotechnology, demonstrating consistent innovation in converting amyloid polymorphism into functional platforms. No scientific awards were documented in available sources. Dr. Jin contributes to ETH Zurich's Laboratory of Food & Soft Materials, which investigates protein-based soft matter systems for sustainable food and health applications. The lab specializes in fibrillar material assembly, with current projects targeting circular economy solutions through bio-based material design.
Professor Roland J. Pieters is a distinguished academic at Utrecht University's Faculty of Science, where he serves as a full Professor in the Department of Chemical Biology and Drug Discovery. With over two decades of experience at the institution, he has progressed from Assistant Professor (1998) to Associate Professor (2005) and ultimately to Full Professor (2010-present). His research group is internationally recognized for groundbreaking work at the intersection of carbohydrate chemistry, chemical biology, and drug discovery, with particular emphasis on developing novel therapeutic approaches against bacterial infections and pathogenic mechanisms. Full Professor, Utrecht University (2010-present) Associate Professor, Utrecht University (2005-2010) Assistant Professor, Utrecht University (1998-2005) NWO Talent Post-doctoral Fellow, ETH-Zürich (1995-1996) Postdoctoral Researcher, University of Groningen (1996-1998) Professor Pieters earned his M.Sc. in Organic Chemistry from the University of Groningen in 1990, where he worked with Professor Ben Feringa, and completed his Ph.D. at MIT in 1995 under the supervision of Professor Julius Rebek Jr. His doctoral research focused on molecular recognition and template effects in bisubstrate systems, establishing the foundation for his lifelong interest in molecular interactions. Professor Pieters' research primarily centers on glycodrugs and the strategic interference with protein-carbohydrate interactions using multivalent systems of varying architectures. His laboratory has made significant contributions to understanding how rigid spacers in multivalent ligands can dramatically enhance binding affinity to target proteins, with applications against viral and bacterial adhesion proteins, toxins, galectins, and glycosidases. A particular focus has been on developing inhibitors for Pseudomonas aeruginosa lectin LecA, cholera toxin, influenza virus hemagglutinin, and more recently, SARS-CoV-2 spike protein interactions with host cell receptors. His group also pioneered the use of glyco- and peptide-microarrays for high-throughput screening of carbohydrate-protein interactions and drug discovery, particularly in the area of O-GlcNAcylation research. The publication record of Professor Pieters demonstrates consistent innovation in the field of multivalent carbohydrate-based therapeutics. His recent work (2020-2024) shows a strategic expansion into viral pathogenesis (particularly influenza and SARS-CoV-2), immune modulation through glycan recognition, and novel approaches to vaccine development. A notable trend is the increasing sophistication of multivalent architectures, moving from simple divalent systems to tetra- and hexavalent ligands with precisely engineered spatial arrangements. His research bridges fundamental chemical principles with practical therapeutic applications, maintaining strong connections to pharmaceutical development while advancing basic science understanding of carbohydrate-mediated biological processes. Professor Pieters' scientific achievements have been recognized with prestigious awards including a Fellowship from the Royal Netherlands Academy of Arts and Sciences (KNAW) in 1999 and a VICI personal grant from the Netherlands Organisation for Scientific Research (NWO) in 2008. These competitive awards reflect the significance and innovation of his research program. He has also served on editorial advisory boards, notably as Section Editor-in-Chief for Chemical Biology in the journal Molecules (2018-2022), contributing to the scholarly community through peer review and academic leadership. Fellowship of Royal Netherlands Academy of Sciences (KNAW), 1999 VICI, personal grant, NWO, 2008 Section Editor-in-Chief Chemical Biology for Molecules (2018-2022) Throughout his career, Professor Pieters has coordinated significant research projects including the EU project POLYCARB and secured competitive funding that has sustained his innovative research program. His laboratory has fostered numerous collaborations across Europe and internationally, creating a vibrant research environment that has trained many scientists now working in academia and industry. His research on multivalent carbohydrate systems represents a sustained intellectual contribution to chemical biology with direct relevance to developing new anti-infective strategies and therapeutic approaches. Professor Pieters leads an active research group within Utrecht University's Department of Chemical Biology and Drug Discovery, situated in the David de Wied Building. His laboratory maintains strong connections with other research groups both within Utrecht University and internationally, particularly in the fields of glycobiology, infectious diseases, and drug discovery. The research environment he has cultivated emphasizes interdisciplinary approaches, combining synthetic chemistry, biophysical analysis, and biological testing to address fundamental questions in carbohydrate-mediated biological processes with therapeutic applications.
